// App-Quantinova.ai

512 : Reduced Intensity Fludarabine and Intravenous Busulfan (FB2) for Allogeneic Peripheral Blood Stem Cell Transplantation

Researchers

Presenter

  • Parikshit Padhi

Principal Investigators

  • Entezam A Sahovic

  • Santhosh Sadashiv

  • Gina Berteotti

  • James Rossetti

  • Cyrus Khan

  • John Lister

Medical Centers

  • Western Pennsylvania Cancer Institute, Allegheny Health Network, Pittsburgh, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Lymphocytic Leukemia

  • Graft-versus-host disease

  • Alpha-thalassemia myelodysplasia syndrome

  • Acute myelocytic leukemia

  • Non-Hodgkin's Lymphoma

  • Hodgkin's Lymphoma

  • Aplastic anemia

  • Lymphomas

  • Anemia

Biomarkers

  • N/A

Drug/Treatment

  • Mycophenolate mofetil

  • CKD-4101

  • fludarabine tablet

  • Tacrolimus

  • Busulfan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved